Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 210 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Kidney Rejection Transplant Clear all

Conditions: Kidney Transplant Rejection
Interventions: TruGraf® Testing; Diagnostic Test
Lead sponsor: Transplant Genomics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kidney Transplant Rejection
Interventions: Patients monitored with TruGraf and TRAC testing; Diagnostic Test
Lead sponsor: Transplant Genomics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 36
States / cities: Tucson, Arizona • Fresno, California • La Jolla, California + 28 more

Conditions: Antibody-mediated Rejection, Microvascular Inflammation
Interventions: Felzartamab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Rochester, Minnesota + 9 more

Conditions: Renal Transplant Rejection, Transplants and Implants
Interventions: Thymoglobulin; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Antibody-mediated Rejection
Interventions: C1-esterase inhibitor, Placebo; Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 9 more

Conditions: Transplant;Failure,Kidney, Kidney Transplant, Kidney Rejection Transplant
Interventions: Not listed
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 100 Years
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Transplantation, Kidney Disease, Kidney Failure, Chronic
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 80 Years
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 5
States / cities: Chicago, Illinois • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Kidney; Complications, Allograft, Transplantation Infection
Interventions: Immunosuppressive Agents; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 2 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: End Stage Renal Disease, Renal Transplant
Interventions: Anti-Thymocyte Globulin, TOL101, Steroids, Tacrolimus, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Tolera Therapeutics, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 12
States / cities: Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more

Conditions: DGF, Kidney Transplant; Complications
Interventions: Highly suppressive Treg measurement; Diagnostic Test
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: San Bernardino, California • St Louis, Missouri

Conditions: Graft Rejection, Kidney Disease
Interventions: Alemtuzumab and DSG; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: End-stage Renal Failure, Kidney Graft Rejection
Interventions: Blood drawing for immune monitoring and questionnaires; Other
Lead sponsor: University of Regensburg; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: Transplantation, Kidney
Interventions: Tacrolimus (TAC), VEL-101; Drug
Lead sponsor: Asahi Kasei Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Kidney Transplant
Interventions: Eculizumab; Drug
Lead sponsor: Mark Stegall; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Graft Rejection
Interventions: Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib, Acetaminophen, Antihistamine, Methylprednisolone; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Rejection Chronic Renal
Interventions: Belumosudil 200 mg QD, Placebo; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Kidney Transplant Failure and Rejection
Interventions: immediate-release tacrolimus, extended release tacrolimus; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Graft Rejection
Interventions: Placebo, C1 Esterase Inhibitor (Human); Biological
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more

Conditions: Kidney Transplant Rejection, Immunosuppression
Interventions: Allosure, Immunosuppression reduction, Trugraf; Diagnostic Test · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Transplant Rejection
Interventions: Feraheme, MRI-GE Healthcare 3 Tesla magnet; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 40 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Renal Transplant, Renin-Angiotensin System, Rejection Acute Renal, Rejection Chronic Renal, Rejection of Renal Transplant
Interventions: Renal Transplantation; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 1 Year to 20 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Renal Transplant Rejection
Interventions: Rituximab, No Rituximab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 2
States / cities: Birmingham, Alabama • San Francisco, California

Conditions: Kidney Transplantation
Interventions: Cyclosporine, CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 37
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Kidney Transplant Recipients
Interventions: Not listed
Lead sponsor: CareDx; Industry
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 10 more

Search by objective public record fields.

TruGraf® Testing in High-Risk Kidney Transplant Recipients

TruGraf® Long-term Clinical Outcomes Study

A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)

Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients

Urine Testing to Detect Kidney Transplant Rejection

The Role of B Cells in Kidney Allograft Dysfunction

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

Highly Suppressive Treg in Delayed and Slow Graft Function After Kidney Transplantation

Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys

Reference Group Trial for The ONE Study

VEL-101 to Prevent Rejection After Kidney Transplantation

Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant

Randomized Trial for Mixed Acute Rejection

Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

Immune Monitoring to Facilitate Belatacept Monotherapy

Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance

Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)

The Effect of Rituximab on the Development of Anti-Donor Antibodies

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Non Invasive Blood Test To Diagnose Acute Rejection After Kidney Transplantation